Mycophenolate mofetil in liver transplantation

Clinical Transplantation

Volumn 10, Issue 1 II, 1996, Pages 140-145

  McDiarmid, Sue V ^a  

^a UCLA MEDICAL CENTER   (United States)

Author keywords

Liver transplantation; Mycophenolate mofetil; Pharmacokinetics; Prophylaxis; Rejection

Indexed keywords

CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PREDNISONE; STEROID;

ADOLESCENT; ADULT; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; CYTOMEGALOVIRUS INFECTION; DIARRHEA; DRUG CLEARANCE; DUODENUM ULCER; ESOPHAGITIS; FEMALE; GASTRITIS; GRAFT REJECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LEUKOPENIA; LIVER TRANSPLANTATION; MALE; ORAL DRUG ADMINISTRATION; PANCREATITIS; PANCYTOPENIA; PRIORITY JOURNAL;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; CYCLOSPORINE; CYTOMEGALOVIRUS INFECTIONS; DIARRHEA; FEMALE; FOLLOW-UP STUDIES; GLUCOCORTICOIDS; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LEUKOPENIA; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; PREDNISONE; RECURRENCE;

EID: 0029868671     PISSN: 09020063     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (23)

1. MCDIARMID SV, COLONNA JQ, SHAKED A, AMENT ME, BUSUTTIL RW. A comparison of renal function in cyclosporine and FK506 treated patients after primary orthotopic liver tranplantation. Transplantation 1993: 56: 847.
2. EIDELMAN BH, ABU-ELMAGD K, WILSON JM, et al. Neurologic complications of FK506. Transplant Proc 1991: 23: 3175.
3. SCOTT JP, HIGENBOTTAM J. Adverse reactions and interactions of cyclosporine. Med Toxicol 1988: 13: 107.
4. JOHANSSON A, MOLLER E. Evidence that the immunosuppressive effects of FK506 and cyclosporine are identical. Transplantation 1990: 50: 1001.
5. EUGUI EM, MIRKOVICH A. ALLISON AC. Lymphocyte-selective antiproliferative and immunosuppressive effects of mycophenolic acid in mice. Scand J Immunol 1991: 33: 175.
6. ALLISON AC, HOVI T, WATTS RW, WEBSTER AD. The role of de novo purine synthesis in lymphocyte transformation. Ciba Found Symp 1977: 207.
7. BECHSTEIN WO, SCHILLING M, STEELE DM, HULLETT DA, SOLLINGER HW. RS-61443/cyclosporine combination therapy prolongs canine liver allograft survival. Transplant Proc 1993: 25: 702.
8. STARZL TE, ABU-ELMAGD K, TZAKIS A, et al. Selected topics on FK. 506. with special references to rescue of extrahepatic whole organ grafts, transplantation of "forbidden organs." side effects, mechanisms, and practical pharmacokinetics. Transplant Proc 1991: 23: 914.
9. YOUNG CJ, SOLLINGER HW. RS-61443: a new immunosuppressive agent. Transplant Proc 1994: 26: 3144.
10. FREISE CE, HEBERT M, OSORIO RW, et al. Maintenance immunosuppression with prednisone and RS-61443 alone following liver transplantation. Transplant Proc 1993: 25: 1758.
11. HEBERT M, BENET LZ, GOMEZ G, et al. Pharmacokinetics (PK) of oral mycophenolate mofetil (MM) in liver transplant patients. Clin Pharmacol Ther 1994; 164. Abstract.
12. KLINTMALM GB, ASCHER NL, BUSUTTIL RW, et al. RS-61443 for treatment-resistant human liver rejection. Transplant Proc 1993: 25: 697.
13. HEBERT M, LAKE J, LINNA TJ, et al. Mycophenolate mofetil for prophylaxis against rejection following orthotopic liver transplantation. 15th World Congress of the Transplantation Society 1994; 343. Abstract.
14. OCHIAI T, GUNJI Y, NAGATA M, ASANO T, ISONO K. Effective and safe use of FK 506: combination treatment with rapamycin or RS-61443 in experimental organ transplantation. Transplant Proc 1991: 23: 2718.
15. ABU-ELMAGD K, FUNG JJ, ALESSIANI M, et al. The effect of graft function on FK506 plasma levels, dosages, and renal function with particular reference to the liver. Transplantation 1991: 52: 71.
16. STEELE DM, HULLETT DA, BECHSTEIN WO, et al. Effects of immunosuppressive therapy on the rat aortic allograft model. Transplant Proc 1993: 25: 754.
17. SOKOLOSKI JA, BLAIR OC, SARTORELLI AC. Alterations in glycoprotein synthesis and guanosine triphosphate levels associated with the differentiation of HL-60 leukemia cells produced by inhibitors of inosine 5′-phosphate dehydrogenase. Cancer Res 1986: 46: 2314.
18. KNECHTLE SJ, WANG J, BURLINGHAM WJ, et al. The influence of RS-61443 on antibody-mediated rejection. Transplantation 1992: 53: 699.
19. EUGUI EM, ALMQUIST SJ, MULLER CD, ALLISON AC. Lymphocyte-selective cytostatic and immunosuppressive effects of mycophenolic acid in vitro: role of deoxyguanosine nucleotide depletion. Scand J Immunol 1991: 33: 161.
20. SOKAL EM, CARAGIOZOGLOU T, LAMY M, REDING R, OTTE JE. Epstein-Barr virus serology and Epstein-Barr virus associated lymphoproliferative disorders in pediatric liver transplant patients. Transplantation 1993: 56: 1394.
21. HO M, JAFFE R, MILLER G, et al. The frequency of Epstein-Barr virus infection and associated lymphoproliferative syndrome after transplantation and its manifestations in children. Transplantation 1988: 45: 719.
22. RENARD TH, ANDREWS WS, FOSTER ME. Relationship between OKT3 administration, EBV seroconversion, and the lymphoproliferative syndrome in pediatric liver transplant recipients. Transplant Proc 1991: 23: 1473.
23. COX KL, LAWRENCE-MIYASAKI LS, GARCIA-KENNEDY R, et al. An increase incidence of Epstein-Barr virus infection and lymphoproliferative disorder in young children on FK506 after liver transplantation. Transplantation 1995: 59: 524.